Article Details

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Retrieved on: 2022-08-31 05:24:15

Tags for this article:

Click the tags to see associated articles and topics

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650. View article details on hiswai:

Excerpt

GTB-3650's IND application with the FDA expected by end of first quarter of 2023 GT Biopharma, Inc. (the "Company" or "GTB") GTBP, ...

Article found on: www.einnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up